Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Renal Denervation in Chronic Kidney Disease - RDN-CKD Study

NCT: NCT07742787 · ACTIVE_NOT_RECRUITING

NCT IDNCT07742787
StatusACTIVE_NOT_RECRUITING
Start Date2024-07-04
Completion2027-03-07
SponsorHippocration General Hospital (OTHER)
First posted
Last updated

Brief Summary

RDN-CKD GR Study is a prospective, randomized (1:1), double-blind (unblinded interventionalist and blinded study team), sham controlled study. The purpose of the RDN-CKD GR Study is to demonstrate that renal denervation (RDN) effectively reduces 24-h ambulatory BP in 20 patients with chronic kidney disease (CKD) stage 3a or 3b.

Frequently Asked Questions

What is Renal Denervation in Chronic Kidney Disease - RDN-CKD Study?

Renal Denervation in Chronic Kidney Disease - RDN-CKD Study is a clinical trial registered under NCT07742787. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT07742787?

The current status of NCT07742787 (Renal Denervation in Chronic Kidney Disease - RDN-CKD Study) is: ACTIVE_NOT_RECRUITING.

When did Renal Denervation in Chronic Kidney Disease - RDN-CKD Study start?

Renal Denervation in Chronic Kidney Disease - RDN-CKD Study started on 2024-07-04.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑